The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Published version of a preprint
Abstract
Somatic gain-of-function mutations in isocitrate dehydrogenases (IDH) 1 and 2 are found in multiple hematologic and solid tumors, leading to accumulation of the oncometabolite (R)-2-hydroxyglutarate (2HG). 2HG competitively inhibits α-ketoglutarate–dependent dioxygenases, including histone demethylases and methylcytosine dioxygenases of the TET family, causing epigenetic dysregulation and a block in cellular differentiation. In vitro studies have provided proof of concept for mutant IDH inhibition as a therapeutic approach. We report the discovery and characterization of AG-221, an orally available, selective, potent inhibitor of the mutant IDH2 enzyme. AG-221 suppressed 2HG production and induced cellular differentiation in primary human IDH2 mutation–positive acute myeloid leukemia (AML) cells ex vivo and in xenograft mouse models. AG-221 also provided a statistically significant survival benefit in an aggressive IDH2R140Q-mutant AML xenograft mouse model. These findings supported initiation of the ongoing clinical trials of AG-221 in patients with IDH2 mutation–positive advanced hematologic malignancies. Significance: Mutations in IDH1/2 are identified in approximately 20% of patients with AML and contribute to leukemia via a block in hematopoietic cell differentiation. We have shown that the targeted inhibitor AG-221 suppresses the mutant IDH2 enzyme in multiple preclinical models and induces differentiation of malignant blasts, supporting its clinical development. Cancer Discov; 7(5); 478–93. ©2017 AACR. See related commentary by Thomas and Majeti, p. 459. See related article by Shih et al., p. 494. This article is highlighted in the In This Issue feature, p. 443
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A specific inhibitor of mutant IDH2, AG-221 (enasidenib) confers survival benefit in a mouse model of IDH2-mutant AML (Quivoron et al., 2014; Yen et al., 2017) and became the first compound targeting mutant IDH to enter clinical trials in 2014. Early results in IDH2-mutant AML patients have suggested enasidenib can provide clinical benefit (DiNardo et al., 2015; Stein et al., 2014), and this drug”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yen et al., 2017
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,961
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“Metabolic reprogramming is a hallmark of cancer, contributing to the initiation and maintenance of tumors (1, 2).”
BackgroundAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Self-citationFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citationIDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,282
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Self-citationMarcucci, G., Maharry, K. S., Wu, Y.-Z., Radmacher, M. D., Mrózek, K., Margeson, D., Holland, K. B., Whitman, S. P., Becker, H., Schwind, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3730 · Cited by 785
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Self-citationBorger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
Self-citationTransformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727
Self-citationCorces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324297111 · Cited by 705
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Losman, J.-A., & Kaelin, W. G. (2013) · Genes & Development · doi:10.1101/gad.217406.113 · Cited by 570
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brüstle, A., Harris, I. S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) · Nature · doi:10.1038/nature11323 · Cited by 513
Self-citationMutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Saha, S. K., Parachoniak, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem, M. S., Gurumurthy, S., Akbay, E. A., Sia, D., Cornellà, H., et al. (2014) · Nature · doi:10.1038/nature13441 · Cited by 460
Self-citationGranulopoiesis and granules of human neutrophils
Cowland, J. B., & Borregaard, N. (2016) · Immunological Reviews · doi:10.1111/imr.12440 · Cited by 405
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
DiNardo, C. D., Ravandi, F., Agresta, S., Konopleva, M., Takahashi, K., Kadia, T., Routbort, M., Patel, K. P., Brandt, M., Pierce, S., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24072 · Cited by 325
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Green, C. L., Evans, C. M., Zhao, L., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2011) · Blood · doi:10.1182/blood-2010-12-322479 · Cited by 272
Kosmider, O., Gelsi‐Boyer, V., Slama, L., Dreyfus, F., Beyne‐Rauzy, O., Quesnel, B., Hunault, M., Slama, B., Vey, N., Lacombe, C., et al. (2010) · Leukemia · doi:10.1038/leu.2010.52 · Cited by 257
Self-citationBoissel, N., Nibourel, O., Renneville, A., Gardin, C., Reman, O., Contentin, N., Bordessoule, D., Pautas, C., de Revel, T., Quesnel, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.2285 · Cited by 229
Merlevede, J., Droin, N. M., Qin, T., Meldi, K. M., Yoshida, K., Morabito, M., Chautard, É., Auboeuf, D., Fenaux, P., Braun, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms10767 · Cited by 225
Self-citationProto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
Kats, L. M., Reschke, M., Taulli, R., Pozdnyakova, O., Burgess, K., Bhargava, P., Straley, K. S., Karnik, R., Meissner, A., Small, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2013.12.016 · Cited by 200
Self-citationChen, C., Liu, Y., Lü, C., Cross, J. R., Morris, J. P., Shroff, A., Ward, P. S., Bradner, J. E., Thompson, C. B., & Lowe, S. W. (2013) · Genes & Development · doi:10.1101/gad.226613.113 · Cited by 186
Kernytsky, A. M., Wang, F., Hansen, E., Schalm, S. S., Straley, K. S., Gliser, C., Yang, H. Q., Travins, J. M., Murray, S., Dorsch, M., et al. (2014) · Blood · doi:10.1182/blood-2013-10-533604 · Cited by 181
Self-citationNew IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Okoye-Okafor, U. C., Bartholdy, B., Cartier, J., Gao, E. N., Pietrak, B., Rendina, A. R., Rominger, C., Quinn, C., Smallwood, A., Wiggall, K. J., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1930 · Cited by 180
Induction of sarcomas by mutant IDH2Preprint
Lü, C., Venneti, S., Akalin, A., Fang, F., Ward, P. S., Dematteo, R. G., Intlekofer, A. M., Chen, C., Ye, J., Hameed, M., et al. (2013) · Genes & Development · doi:10.1101/gad.226753.113 · Cited by 162
Fathi, A. T., Sadrzadeh, H., Borger, D. R., Ballen, K. K., Amrein, P. C., Attar, E. C., Foster, J., Burke, M. E., Lopez, H. U., Matulis, C. R., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438267 · Cited by 125
Self-citationYang, B., Zhong, C., Peng, Y., Lai, Z., & Ding, J. (2010) · Cell Research · doi:10.1038/cr.2010.145 · Cited by 121
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
Dinardo, C. D., Jabbour, E. J., Ravandi, F., Takahashi, K., Daver, N. G., Routbort, M. J., Patel, K. P., Brandt, M., Pierce, S. A., Kantarjian, H. M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.211 · Cited by 115
A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHG
Pietrak, B., Zhao, H., Qi, H., Quinn, C. J., Gao, E. N., Boyer, J. G., Concha, N. O., Brown, K., Duraiswami, C., Wooster, R. F., et al. (2011) · Biochemistry · doi:10.1021/bi200499m · Cited by 112
Anoxia and glucose supplementation preserve neutrophil viability and function
Monceaux, V., Chiche-Lapierre, C., Chaput, C., Witko‐Sarsat, V., Prévost, M., Taylor, C. T., Ungeheuer, M., Sansonetti, P. J., & Marteyn, B. (2016) · Blood · doi:10.1182/blood-2015-11-680918 · Cited by 82
Self-citationStein, E. M., Dinardo, C. D., Altman, J. K., Collins, R. H., DeAngelo, D. J., Kantarjian, H. M., Sekeres, M. A., Fathi, A. T., Flinn, I. W., Frankel, A. E., et al. (2015) · Blood · doi:10.1182/blood.v126.23.323.323 · Cited by 72
Self-citationБей, Yang, Chen, Zhong, Yingjie, ......................................................, P., Zheng, Lai, Jianping, & Ding (2010) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 67
Hu, S., Niu, H., Inaba, H., Orwick, S. J., Rose, C., Panetta, J. C., Yang, S., Pounds, S. B., Fan, Y., Calabrese, C. R., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr107 · Cited by 53
Poinsignon, V., Mercier, L., Nakabayashi, K., David, M. D., Lalli, A., Penard‐Lacronique, V., Quivoron, C., Saada, V., de Botton, S., Broutin, S., et al. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.04.030 · Cited by 43
Self-citationClonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia
Sykes, S. M., Kokkaliaris, K. D., Milsom, M. D., Levine, R. L., & Majeti, R. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.08.012 · Cited by 32
Flagged first, then by citations
Cited by
Sorted by citations
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
Meanwell, N. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01788 · Cited by 2,734
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,813
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
“Age, median (range), y 67 (19-100) 67 (19-100) 70 (19-100)”
Self-citationDurable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
Dinardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R. T., Collins, R. H., Mannis, G. N., Pollyea, D. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716984 · Cited by 1,507
“Treatment-related AML 14/125 (11) 16/179 (9) 22/242 (9)”
Self-citationTargeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
“A specific inhibitor of mutant IDH2, AG-221 (enasidenib) confers survival benefit in a mouse model of IDH2-mutant AML (Quivoron et al., 2014; Yen et al., 2017) and became the first compound targeting mutant IDH to enter clinical trials in 2014.”
BackgroundInfluential
Metadata
- Authors
- Yen, K., Travins, J., Wang, F., David, M. D., Artin, E., Straley, K., Padyana, A., Gross, S., DeLaBarre, B., Tobin, E., Chen, Y., Nagaraja, R., Choe, S., Jin, L., Konteatis, Z., Cianchetta, G., Saunders, J. O., Salituro, F. G., Quivoron, C., Opolon, P., Bawa, O., Saada, V., Paci, A., Broutin, S., Bernard, O. A., de Botton, S., Marteyn, B. S., Pilichowska, M., Xu, Y., Fang, C., Jiang, F., Wei, W., Jin, S., Silverman, L., Liu, W., Yang, H., Dang, L., Dorsch, M., Penard-Lacronique, V., Biller, S. A., & Su, S.-S. M.
- Affiliations
- Agios Pharmaceuticals (United States) (US)
- Inserm (FR)
- 1Agios Pharmaceuticals, Inc., Cambridge, Massachusetts.
- Université Paris-Saclay (FR)
- 6Service de Pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
- 2INSERM U1170, Villejuif, France.
- Tufts Medical Center (US)
- 11ShangPharma, Shanghai, China.
- Viva Biotech (China) (CN)
- Corresponding author
- Su, Shin-San Michael
- ORCID
- Yen, Katharine
- Wang, Fang
- David, Muriel D.
- Padyana, Anil
- Tobin, Erica
- Chen, Yue
- Choe, Sung
- Jin, Lei
- Konteatis, Zenon
- Salituro, Francesco G.
- Quivoron, Cyril
- Opolon, Paule
- Bawa, Olivia
- Saada, Véronique
- Broutin, Sophie
- Bernard, Olivier A.
- Marteyn, Benoît S.
- Pilichowska, Monika
- Jiang, Fan
- Wei, Wentao
- Liu, Wei
- Yang, Hua
- Dang, Lenny
- Venue
- Cancer Discovery
- Published
- 2017-04-30
- Volume
- 7
- Issue
- 5
- Pages
- 478-493
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2588385654
- Cited by
- 471
- References
- 52
- Citations by year
- 2026: 35 · 2025: 47 · 2024: 51 · 2023: 46 · 2022: 48 · 2021: 78 · 2020: 55 · 2019: 37 · 2018: 51 · 2017: 23
- FWCI
- 34.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (INCa-DGOS-Inserm_6043 and INCa 2012-1-RT-09)
- Association pour la Recherche sur le Cancer (SL220130607089)
- Institut National Du Cancer (INCa-DGOS_5733)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH2 inhibitors, acute myeloid leukemia, IDH2 mutation, 2-hydroxyglutarate, oncometabolites, hematopoietic differentiation, TET methylcytosine dioxygenases, histone demethylase, xenograft mouse model
- MeSH terms
- Aminopyridines, Animals, Antineoplastic Agents, Humans, Isocitrate Dehydrogenase, Mutation, Triazines, Leukemia, Myeloid, Acute, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
